The poly (ADP‐ribose) polymerase 1 (PARP1) gene, the synthetic lethal pair of BRCA1, however, is conserved in most of the BRCA1m cancer cells and thus may be a fruitful target for TNBC therapy.7 Neither PARP1 inhibition alone nor BRCA1 deficiency alone is lethal, but the combination of the two is, suggesting a therapeutic strategy that leverages this synthetic lethality. The gene discussed is BRCA1; the disease is cancer.